PCR-ribotyping
PCR-ribotyping was performed on all isolates following the Clostridium difficile Ribotyping Network of England and Northern Ireland protocol 3 .
Statistical Methods
For sample size calculations for the laboratory assessment we assumed testing algorithm sensitivity and specificity of 90% and 99·5%, respectively, with 4·5% of samples positive; thus, 8,000-10,000 specimens will estimate sensitivity within 3% and specificity within 0·2%.
The rationale is that for a randomly sampled (negative, positive) reference test pair, the AUROC is the probability that the test (t) ranks a true positive as more likely infected than a true negative (i.e. tp > tn). For each test algorithm we used 1000 bootstrap samples for the AUROC, estimated via randomly selected record pairs, (tp, tn); the proportion of pairs where tp > tn is the AUROC. For testing the significance of difference between two AUROCs we used the distributional form of their difference coming from 2000 bootstrap samples. The Boostrap sample size of 1000 was chosen for consistency in the estimates with a standard error within 0·1% of the estimate
Additional results
The toxin EIA 1 and Xpert assays were not used first line in the testing phase, and so represent a smaller and partially selected dataset (table 1); the toxin EIA 1 assay was used during the testing phase at one site (n=2558) as this was the routine test there. In the training phase (n=6753) 389, 559 and 704 samples were CTA, CC and NAAT positive.
The sensitivity of toxin EIA 1 and toxin EIA 2 was 66·9% (62·7-70·8% 95% CI) and 83·2% (80·3-85·8% 95% CI), respectively, compared with CTA. Toxin EIA 1 also showed the highest variability between sites when AUROCs were examined, further demonstrating the poor performance of this test (table 4) .
Episodes with missing clinical or death data are more likely to be female, older and have been in hospital for longer (p<0.0001): median age 74 (missing) vs 68 years of age (with data); 62% female (missing) vs 53% (with data), median los (at testing) 6 days (missing) 5 days (with data).
As some patients were tested more than once, we needed to check for within-patient correlation in the results. We did this by means of multi-level analysis through a logistic regression model where the outcome was either one of the gold standard tests (cytotoxigenic culture or cytotoxin test) and found that the random effects model invariably fitted the data significantly better than the random effects model, with large intraclass correlation coefficients (ICC). We compared negative twice the difference in log-likelihoods between models against the Chi-square distribution to assess the fit to the data, as advocated by Twisk 4 . When we used the deduplicated data set, where samples for the same episode were removed, the ICC became non-significant. Repeating the analyses using just the deduplicated set of episodes (within a 28 day window), did not lead to important changes in the results, although the standard errors were slightly larger". A "real world" clinical laboratory will be using multiple samples for each patient and this was an additional reason for keeping the main table in the manuscript showing the results for the full samples as received by the laboratory.
Ribotyping
The isolates comprised 114 different PCR-ribotypes. Ten PCR-ribotypes accounted for 63% of all of the isolates, which were (in rank order) 015, 014, 027, 002, 010, 005, 078, 140, 026, and 020.
Inter-laboratory variation
The monthly quality assurance samples yielded no discordant results between laboratories. There were variations in performance of each assay across the laboratories during the training phase shown by AUROC analysis (table 4). The largest inter-site variation was seen with the toxin EIA 1 (coefficient of variation = 8·08% and 7·35% for CTA and CC, respectively). The correlation between the positivity rates of each assay over the time of the study was fairly consistent (figure 4). Time series plots showing the positivity rate of each assay during the study by site showed the same stacking pattern of the assays and confirmed that intra-and inter-site variability mirrored that seen in the study as a whole (data not shown).
Previous studies have often been single centre and so have been unable to determine inter-laboratory variation in performance between commercial assays and have been subject to variable strain distributions, which may introduce bias. Inter-site variation in this study was demonstrated by AUROC analysis (table 4) . Indeed, if performed only at St George's (n= 1593) for example, toxin EIA 1 had the highest AUROC of all single assays in the testing phase compared with CTA, in contrast with overall results. The reasons for this variability are manifold, and could include the prevalence of PCRribotypes 5 . However, only ten PCR-ribotypes represented 63% of all study isolates, and PCR-ribotypes 014 and or 015 were found amongst the three most common types at each site. Comparing positivity rates for each assay at each centre showed the same trends in variability between sites. This indicates that intrinsic assay factors are likely to be affecting performance. 
